Pages that link to "Q36666922"
Jump to navigation
Jump to search
The following pages link to The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism (Q36666922):
Displaying 50 items.
- Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients (Q24187385) (← links)
- Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials (Q26851487) (← links)
- Cinacalcet versus standard treatment for chronic kidney disease: a protocol for a systematic review and meta-analysis (Q28079300) (← links)
- Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis (Q28484646) (← links)
- Upregulation of parathyroid VDR expression by extracellular calcium is mediated by ERK1/2-MAPK signaling pathway (Q28580368) (← links)
- Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis (Q30251450) (← links)
- A Computerized Treatment Algorithm Trial to Optimize Mineral Metabolism in ESRD (Q30421529) (← links)
- Pharmacotherapy of end-stage renal disease (Q33531889) (← links)
- Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. (Q33571321) (← links)
- The effects of discontinuing cinacalcet at the time of kidney transplantation (Q33597429) (← links)
- Calciphylaxis in chronic renal failure: An approach to risk factors (Q33809841) (← links)
- The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis (Q34293730) (← links)
- Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism (Q34362759) (← links)
- Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism? (Q34366087) (← links)
- Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study (Q34739121) (← links)
- Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs (Q35026640) (← links)
- Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism (Q35245052) (← links)
- Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism (Q35545384) (← links)
- The cost-effectiveness of drug therapies to treat secondary hyperparathyroidism in renal failure: a focus on evidence regarding paricalcitol and cinacalcet (Q35635182) (← links)
- Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism (Q35682152) (← links)
- A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM) (Q35682192) (← links)
- Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study (Q35920190) (← links)
- Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis (Q36121519) (← links)
- Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study (Q36199558) (← links)
- Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism. (Q36432849) (← links)
- Cinacalcet improves control of secondary hyperparathyroidism in peritoneal dialysis: a multicenter study (Q36475574) (← links)
- Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction. (Q36880126) (← links)
- Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism (Q37102086) (← links)
- Calcimimetics in chronic kidney disease: evidence, opportunities and challenges (Q37182739) (← links)
- Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift? (Q37310824) (← links)
- Mechanistic analysis for time-dependent effects of cinacalcet on serum calcium, phosphorus, and parathyroid hormone levels in 5/6 nephrectomized rats (Q37328071) (← links)
- Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism (Q37449576) (← links)
- Management of secondary hyperparathyroidism in the elderly patient with chronic kidney disease. (Q37547201) (← links)
- Pharmacotherapy and interventional treatments for secondary hyperparathyroidism: current therapy and future challenges (Q37807991) (← links)
- Derangements in Phosphate Metabolism in Chronic Kidney Diseases/Endstage Renal Disease: Therapeutic Considerations (Q37853254) (← links)
- Treatment with calcimimetic (cinacalcet) alters epoetin dosage requirements in dialysis patients: preliminary report (Q37889300) (← links)
- Does it Matter How Parathyroid Hormone Levels are Suppressed in Secondary Hyperparathyroidism? (Q37891153) (← links)
- Diseases of the parathyroid gland in chronic kidney disease. (Q37912038) (← links)
- Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease (Q37916534) (← links)
- Pharmacotherapy of chronic kidney disease and mineral bone disorder. (Q37948105) (← links)
- Cinacalcet: will it play a role in reducing cardiovascular events? (Q37993874) (← links)
- Paricalcitol and cardiorenal outcome: from the IMPACT study to clinical practice. (Q38111948) (← links)
- Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism. (Q38141236) (← links)
- Emerging drugs for secondary hyperparathyroidism. (Q38363615) (← links)
- Cinacalcet and Clinical Outcomes in Dialysis (Q38565049) (← links)
- Management of secondary hyperparathyroidism: how and why? (Q38775426) (← links)
- Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies. (Q39220825) (← links)
- Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide (Q39374348) (← links)
- Cinacalcet: the chemical parathyroidectomy? (Q39719456) (← links)
- Long-Term Hypoparathyroidism and Hypophosphatemia in Dialysis Patients (Q40479039) (← links)